Abstract: An active discharge circuit for electric vehicle inverter, the active discharge circuit intended to be connected in parallel with a DC link capacitor connected between positive and negative lines of a DC power link, wherein the circuit comprises a dissipative current source, a switch connected in series with the current source between the DC lines, and a controller connected to the switch and arranged to apply an activation signal in dependence of a control signal, the activation signal placing the switch in a conducting state, wherein the current source is configured to draw a discharge current and dissipate any energy stored in the DC link capacitor when the switch is in the conducting state. As long as the switch is closed by the activation signal, the current source will draw a constant current and dissipate power, and the voltage across the DC link capacitor will decrease linearly.

Abstract: An active discharge circuit for electric vehicle inverter, the active discharge circuit intended to be connected in parallel with a DC link capacitor connected between positive and negative lines of a DC power link, wherein the circuit comprises a dissipative current source, a switch connected in series with the current source between the DC lines, and a controller connected to the switch and arranged to apply an activation signal in dependence of a control signal, the activation signal placing the switch in a conducting state, wherein the current source is configured to draw a discharge current and dissipate any energy stored in the DC link capacitor when the switch is in the conducting state. As long as the switch is closed by the activation signal, the current source will draw a constant current and dissipate power, and the voltage across the DC link capacitor will decrease linearly.

Abstract: A pharmaceutical composition for treatment of a pathological condition in a patient comprises, as a first component, a manganese complex of Formula I( ), and, as a second component, a non-manganese complex compound of Formula (I), optionally together with one or more physiologically acceptable carriers and/or excipients, wherein X, R, R, R, and R are as defined herein. Methods for treatment of a pathological condition in a patient, for example, a pathological condition caused by the presence of oxygen-derived free radicals, comprises administering to said patient the first component and the second component.

Abstract: Methods for treatment of a pathological condition caused by oxidative stress in a patient comprise administering to the patient a mixed metal complex of a compound of Formula I, or a salt thereof, in an amount effective to reduce the oxidative stress. Pharmaceutical compositions are formed by suspending or dissolving a mixed metal complex of a compound of Formula I, or a salt thereof, in a liquid medium, optionally with one or more physiologically acceptable excipients. The mixed metals comprise calcium and manganese in a molar ratio of calcium to manganese in the range of 1-10: wherein X, R1, R2, R3, and R4 are as defined herein.

Abstract: Methods for treatment of a pathological condition caused by oxidative stress in a patient comprise administering to the patient a mixed metal complex of a compound of Formula I, or a salt thereof, in an amount effective to reduce the oxidative stress. Pharmaceutical compositions are formed by suspending or dissolving a mixed metal complex of a compound of Formula I, or a salt thereof, in a liquid medium, optionally with one or more physiologically acceptable excipients. The mixed metals comprise calcium and manganese in a molar ratio of calcium to manganese in the range of 1-10: wherein X, R1, R2, R3, and R4 are as defined herein.

Abstract: Methods for treatment of a pathological condition caused by oxidative stress in a patient comprise administering to the patient a mixed metal complex of a compound of Formula I, or a salt thereof, in an amount effective to reduce the oxidative stress. The mixed metals comprise calcium and manganese in a molar ratio of calcium to manganese in the range of 1-10: wherein X, R1, R2, R3, and R4 are as defined herein.

Abstract: The present invention relates to a fluid pump system (64) having a fluid reservoir (21) comprising a first cavity (29) and a second cavity (30) in fluidic communication with each other and adapted to accommodate a biological fluid (7). The fluid reservoir (21) is connected to a fluid-container system (27) and a target (5) is in fluidic communication with the second cavity (30). A pressurization system is adapted to generate a first pressure below ambient pressure in the first cavity (29) and generate a second pressure in the first cavity (29). The second pressure is also applied to the second cavity (30). The fluid pump system (64) thereby causes flow of the biological fluid (7) from the fluid-container system (27) into the first cavity (29), from the first cavity (29) into the second cavity (30), and from the second cavity (30) to the target (5).

Abstract: Methods for treatment of a pathological condition caused by oxidative stress in a patient comprise administering to the patient a mixed metal complex of a compound of Formula I, or a salt thereof, in an amount effective to reduce the oxidative stress. The mixed metals comprise calcium and manganese in a molar ratio of calcium to manganese in the range of 1-10: wherein X, R1, R2, R3, and R4 are as defined herein.

Abstract: A mixed metal complex of a compound of Formula I, or a salt thereof, wherein the mixed metals comprise a Group III-XII transition metal and a Group II metal: wherein X, R1, R2, R3, and R4 are as defined herein, is produced in a one step crystallization from a solution of the Group III-XII transition metal, the Group II metal, and a compound of Formula I. Methods for treatment of a pathological condition in a patient, for example, a pathological condition caused by the presence of oxygen-derived free radicals, comprise administering the mixed metal complex to the patient.

Abstract: Methods for treatment of cancer selected from lung cancer, ovarian cancer, squamous cell carcinoma, pancreas exocrine cancer, malignant melanoma, gastric cancer, esophageal cancer, a metastases thereof, and leukemia, in a human or non-human body, comprise administrating to the body a cancer-inhibiting amount of a first compound of Formula (I): or a physiologically acceptable salt thereof, wherein X, R1, R2, R3 and R4 are as defined herein.

Abstract: The present invention relates to a fluid reservoir (21), said fluid reservoir (21) comprising at least one first cavity (29) and one second cavity (30) in fluidic communication with each other and adapted to accommodate fluid (7), the fluid reservoir (21) further being connected to a fluid-container system (7, 8, 9, II, 22), a fluid consumer (5) in fluidic communication with at least the second cavity (30), a pressurization system (I, 2) adapted to generate a substantially constant pressure, and a vacuum system (58, 59, 60) adapted to generate a pressure below ambient pressure. The invention further comprises a fluid-supply system.

Abstract: A mixed metal complex of a compound of Formula I, or a salt thereof, wherein the mixed metals comprise a Group III-XII transition metal and a Group II metal: (Formula I) (I) wherein X, R1, R2, R3, and R4 are as defined herein, is produced in a one step crystallization from a solution of the Group III-XII transition metal, the Group II metal, and a compound of Formula I. Methods for treatment of a pathological condition in a patient, for example, a pathological condition caused by the presence of oxygen-derived free radicals, comprises administering the mixed metal complex to the patient.

Abstract: The present invention relates to a fluid reservoir (21), said fluid reservoir (21) comprising at least one first cavity (29) and one second cavity (30) in fluidic communication with each other and adapted to accommodate fluid (7), the fluid reservoir (21) further being connected to a fluid-container system (7, 8, 9, II, 22), a fluid consumer (5) in fluidic communication with at least the second cavity (30), a pressurization system (I, 2) adapted to generate a substantially constant pressure, and a vacuum system (58, 59, 60) adapted to generate a pressure below ambient pressure. The invention further comprises a fluid-supply system.

Abstract: The invention relates to an equipment for removing deposits accumulated in electrolytic refining on the surface of an electrode, such as a cathode, said equipment including at least one element for stripping the deposits and at least one element for controlling the stripping element; said equipment includes at least one stripping element that is turnably movable in the vertical direction of the cathode, and the cathode can be bent owing to the contact with said stripping element. The invention also relates to a method realized by said equipment.

Abstract: Pharmaceutical compositions comprise a first compound of Formula I or a physiologically acceptable salt thereof, and a cyto-protective amount of a manganese chelate of N,N?-dipyridoxyl ethylenediamine-N,N?-diacetic acid (MnPLED): wherein R1, R2, R3, R4 and X are defined in the specification.

Abstract: Compound of Formula I or a salt thereof for treating cancer, wherein X represents CH or N; R1 represents hydrogen or —CH2COR5; R5 represents hydroxy, optionally hydroxylated alkoxy, amino or alkylamido; R2 represents ZYR6; Z represents a bond, or a C1-3 alkylene or oxoalkylene group optionally substituted by R7; Y represents a bond, an oxygen atom or NR6; R6 is a hydrogen atom, COOR8, an alkyl, alkenyl, cycloalkyl, aryl or aralkyl group optionally substituted by one or more selected from COOR8, CONR82, NR82, OR8, ?NR8, ?O, OP(O)(OR8)R7 and OSO3M; R7 is hydroxy, an optionally hydroxylated, optionally alkoxylated alkyl or aminoalkyl group; R8 is a hydrogen atom or an optionally hydroxylated, optionally alkoxylated alkyl group; M is a hydrogen atom or one equivalent of a physiologically tolerable cation; R3 represents C1-8 alkylene, 1,2-cykloalkylene, or 1,2-arylene, optionally substituted with R7; and R4 represents hydrogen or C1-3 alkyl.

Abstract: A pharmaceutical composition for treatment of a pathological condition in a patient comprises, as a first component, a manganese complex of Formula I( ), and, as a second component, a non-manganese complex compound of Formula (I), optionally together with one or more physiologically acceptable carriers and/or excipients, wherein X, R, R, R, and R are as defined herein. Methods for treatment of a pathological condition in a patient, for example, a pathological condition caused by the presence of oxygen-derived free radicals, comprises administering to said patient the first component and the second component.

Abstract: The invention relates to a filter mat, which is used in applications where it filters the flows of contaminated air that pass through it. In such mats, there are points where aerosols collect. This is disadvantageous as it lowers the efficiency of the mat. The present invention overcomes this by having, at these points, wicks (2) that absorb said collections.

Abstract: Compound of Formula I or a salt thereof for treating cancer, wherein X represents CH or N; R1 represents hydrogen or —CH2COR5; R5 represents hydroxy, optionally hydroxylated alkoxy, amino or alkylamido; R2 represents ZYR6; Z represents a bond, or a C1-3 alkylene or oxoalkylene group optionally substituted by R7; Y represents a bond, an oxygen atom or NR6; R6 is a hydrogen atom, COOR8, an alkyl, alkenyl, cycloalkyl, aryl or aralkyl group optionally substituted by one or more selected from COOR8, CONR82, NR82, OR8, ?NR8, ?O, OP(O)(OR8)R7 and OSO3M; R7 is hydroxy, an optionally hydroxylated, optionally alkoxylated alkyl or aminoalkyl group; R8 is a hydrogen atom or an optionally hydroxylated, optionally alkoxylated alkyl group; M is a hydrogen atom or one equivalent of a physiologically tolerable cation; R3 represents C1-8 alkylene, 1,2-cykloalkylene, or 1,2-arylene, optionally substituted with R7; and R4 represents hydrogen or C1-3 alkyl.

Abstract: The invention relates to a method for sintering in a furnace atmosphere wherein said furnace atmosphere is a hydrogen-free atmosphere comprising nitrogen and carbon monoxide.